Fruits that cannot be consumed with Herceptin
Nov 13, 2024
Source: Cainiu Health
Dr. Qi Zhirong
Introduction
Herceptin usually refers to trastuzumab. Fruits that should generally not be consumed with trastuzumab include grapefruit, lychee, lemon, persimmon, and pomegranate. Detailed analysis is as follows: During treatment, patients should follow their doctor's advice, maintain a balanced diet, and avoid consuming fruits that may affect the drug's efficacy. At the same time, regular monitoring of drug effectiveness and adverse reactions is recommended.
Herceptin usually refers to trastuzumab. Fruits that should generally not be consumed with trastuzumab include grapefruit, lychee, lemon, persimmon, and pomegranate. Detailed explanations are as follows:
1. Grapefruit
Naringenin in grapefruit may affect drug metabolism. When interacting with monoclonal antibody drugs such as trastuzumab, it could increase the drug concentration in the body, thereby increasing the risk of adverse reactions.
2. Lychee
Lychee contains certain components that may have unknown interactions with trastuzumab, potentially affecting the drug's efficacy or safety. Therefore, consumption should be avoided during treatment.
3. Lemon
Lemons are rich in vitamin C. Although vitamin C is generally safe for most people, excessive intake might accelerate drug excretion, thus reducing the effectiveness of trastuzumab. It is therefore recommended to limit lemon consumption during treatment.
4. Persimmon
Persimmons contain high levels of tannic acid. This substance may bind with certain components of medications, forming indigestible precipitates that interfere with drug absorption and effectiveness.
5. Pomegranate
Pomegranates are rich in antioxidants, which may interact with trastuzumab and affect its metabolism and therapeutic effect. Therefore, pomegranate should also be avoided during treatment.
During treatment, patients should follow their doctor’s advice, maintain a balanced diet, and avoid consuming fruits that may interfere with drug efficacy. Additionally, regular monitoring of treatment response and adverse effects is recommended.
